Security record · archived quarter
SLNO
Soleno Therapeutics, Inc. · Healthcare · Biotechnology
8Tracked holders
0Δ holders
6.39MShares held
$322.73MReported value
+2New positions
−2Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 81 | -6 | 38.38M | $1.28B | +6 | −12 |
| Q4 2025 | 86 | 0 | 43.97M | $2.04B | +1 | −1 |
| Q3 2025 | 17 | -1 | 29.19M | $1.97B | — | −1 |
| Q2 2025 | 15 | -1 | 21.84M | $1.83B | +1 | −2 |
| Q1 2025 | 13 | +4 | 13.32M | $951.87M | +4 | — |
| Q4 2024 | 9 | 0 | 8.99M | $404.33M | — | — |
| Q3 2024 | 8 | 0 | 6.39M | $322.73M | +2 | −2 |
| Q2 2024 | 8 | — | 4.85M | $197.82M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.32M | +16.4% | $167.74M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.31M | +174.0% | $66.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.31M | +174.0% | $66.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 683.17K | +73.8% | $34.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 540.30K | +10.5% | $27.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 540.30K | +10.5% | $27.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Millennium Management ✦ | 254.89K | -44.4% | $12.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 247.84K | New | $12.51M | 0.0% | New | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 21.74K | +167.5% | $1.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 12.28K | New | $619,916 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 12.28K | New | $619,916 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $12.51M | 0.0% |
| AQR Capital Management | $619,916 | 0.0% |
| AQR Capital Management | $619,916 | 0.0% |
Exited
| Soros Fund Management | $4.49M | was 0.1% |
| Norges Bank | $2.36M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 55.22M shares, $1.81B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API